Health insurance company Humana (NYSE: HUM) will be reporting results tomorrow before market hours. Here’s what you need to know.
Humana beat analysts’ revenue expectations by 1.1% last quarter, reporting revenues of $29.21 billion, up 10.4% year on year. It was a mixed quarter for the company, with full-year revenue guidance exceeding analysts’ expectations but a significant miss of analysts’ full-year EPS guidance estimates. It lost 11,000 customers and ended up with a total of 16.35 million.
Is Humana a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Humana’s revenue to grow 8.1% year on year to $32 billion, slowing from the 10.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $10.07 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Humana has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.1% on average.
Looking at Humana’s peers in the health insurance providers segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 15.4%, beating analysts’ expectations by 8.3%, and Elevance Health reported revenues up 14.8%, topping estimates by 5.3%. Centene traded down 3.3% following the results while Elevance Health was up 4.9%.
Read our full analysis of Centene’s results here and Elevance Health’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.2% on average over the last month. Humana’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $307.01 (compared to the current share price of $263.20).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
